GCVI Summit 2018
Skip Content

11 October 2017

Spero spies opening in public markets

Bacterial infection treatment developer Spero Therapeutics has filed to raise up to $86.3m in an initial public offering that will enable a host of corporates to exit.

Author: Robert Lavine, News Editor

Spero Therapeutics, a US-based bacterial infection therapy developer backed by internet and technology group Alphabet and several corporates in the healthcare sector, has filed for an $86.3m initial public offering.